サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363022

内分泌検査の市場規模、シェア、動向分析レポート：検査タイプ別、技術別、最終用途別、地域別、セグメント予測、2023年～2030年

Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (FSH, Insulin), By Technology (Tandem Mass Spectrometry, Immunoassay), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
内分泌検査の市場規模、シェア、動向分析レポート：検査タイプ別、技術別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月14日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

内分泌検査市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の内分泌検査市場規模は2030年までに214億2,000万米ドルに達し、予測期間中のCAGRは8.4％を記録すると予測されています。

成人だけでなく老年人口における肥満や糖尿病、甲状腺などの生活習慣病の有病率の増加が、内分泌検査の必要性を促進しています。個人における定期的な内分泌検査は、全体的な健康維持に役立つため、より良い健康への意識が世界の内分泌検査市場の成長に大きく寄与しています。

WHOの統計によると、2020年には5歳未満の3,900万人以上の子供たちが過体重または肥満でした。座りっぱなしの生活と不健康な食事の選択が、一般人口の肥満や糖尿病の原因となっています。このような疾病の発生は、代謝機能や関連するホルモン障害に関する多くの研究を促しています。

政府や民間団体からの資金援助も科学界を動かしています。例えば、NIHのNIDDK（国立糖尿病・消化器・腎臓病研究所）は、疾患のより良い理解による健康増進を目指し、多くのスポンサー付き研究プログラムを推進しています。NIDDKによるそのような取り組みのひとつが、2022年9月に行われた糖尿病と肥満研究のための大西洋中部シンポジウムです。これは科学的知識の交換と交流を可能にし、地域レベルでの協力を可能にします。このような取り組みは、人体における内分泌機能の理解を促進し、内分泌検査市場の成長をさらに可能にすると思われます。

低開発国や新興諸国における認識不足は、内分泌検査市場の成長を鈍らせると予想されます。発展途上の医療環境と償還モデルの不在が、これらの地域の個人が定期的な内分泌検査を受けることを抑制しています。しかし、COVID-19の大流行時に健康なシステムに対する意識が高まるにつれて、これらの国々でも検査頻度が上昇すると予想されます。

COVID-19の流行は、内分泌検査の応用に有利な機会を生み出しています。COVID-19感染は、多くの臓器を傷害する全身性疾患を引き起こします。そのため、これらの患者は多くの代謝障害やホルモン障害を抱えており、内分泌研究の増加につながっています。例えば、2021年3月、内分泌学会の会員は、内分泌系に対するCOVID-19の短期および長期の影響を特定し理解するために、COVID-19の研究を支援する100億米ドルを承認しました。同様に、2020年9月、米国糖尿病協会は、糖尿病とCOVID-19の関連を調査するためのさまざまな研究プロジェクトに100万米ドルを投資しました。したがって、需要が増加し、市場の成長がさらに促進されます。

さらに、監禁による移動の制限や制約が、医療相談や自宅でのサンプル採取サービスのためのデジタルプラットフォームを後押ししました。自宅でホルモン値を検出するためのポイントオブケア機器やキットの入手可能性も、内分泌検査市場全体の成長を後押ししています。

市場プレーヤーはまた、内分泌検査市場を成長させると予想される様々な要因により、地域的プレゼンスを拡大しています。コラボレーション、パートナーシップ、世界展開は、収益創出を促進するための主要プレーヤーによる事業戦略の一部です。例えば、2022年2月、Laboratory Corporation of America Holdings（Labcorp）は、米国インディアナ州に新たなラボを開設すると発表しました。インディアナ州サウスベンドでの新たな診断事業は、同社のサービスを強化し、この地域の患者だけでなく医師も利用できるようにします。

内分泌検査市場レポートハイライト

  • 検査タイプ別では、ヒト絨毛性ゴナドトロピン（hCG）ホルモン検査が2022年に最大のシェアを占めました。これは、定量評価のための検査室や病院での検査とともに、薬局での自己検査キットの存在によるものです。さらに、妊娠のさまざまな週における検査の頻度や、妊娠可能な女性人口の多さも一因となっています。
  • 技術別では、イムノアッセイが2022年市場を独占しました。これは、イムノアッセイに基づく検出技術を使用する主要企業による機器の存在によるものです。イムノアッセイ技術に依存する多くの機器と検査パネルが内分泌検査市場の成長を牽引しています。
  • 最終用途別では、商業検査室が2022年の売上に大きく貢献しました。内分泌学と生殖機能のための多様な検査パネルの実現可能性と利用可能性、自宅での採取のようなサービス、デジタルプラットフォームの存在が、セグメントシェアの拡大につながっています。
  • 2022年の内分泌検査市場の売上高は北米が最も高かったです。これは、米国人口に甲状腺疾患、糖尿病、肥満が多く存在するためです。さらに、この地域の医療の発達と支出パターンの増加も、収益増につながっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 内分泌検査市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 内分泌検査市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 内分泌検査：検査タイプの推定・動向分析

  • 内分泌検査市場：重要なポイント
  • 内分泌検査市場：動向と市場シェア分析、2022年および2030年
  • エストラジオール（E2）検査
  • 卵胞刺激ホルモン（FSH）検査
  • ヒト絨毛性ゴナドトロピン（hCG）ホルモン検査
  • 黄体形成ホルモン（LH）検査
  • デヒドロエピアンドロステロン硫酸塩（DHEAS）検査
  • プロゲステロン検査
  • テストステロン検査
  • 甲状腺刺激ホルモン（TSH）検査
  • プロラクチン検査
  • コルチゾール検査
  • インスリン検査
  • その他

第5章 内分泌検査：技術の推定・動向分析

  • 内分泌検査市場：重要なポイント
  • 内分泌検査市場：動向と市場シェア分析、2022年および2030年
  • タンデム質量分析法
  • イムノアッセイ
  • モノクローナルおよびポリクローナル抗体技術
  • センサー技術
  • 臨床化学
  • その他

第6章 内分泌検査：最終用途の推定・動向分析

  • 内分泌検査市場：重要なポイント
  • 内分泌検査市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • 商業検査室
  • 外来診療センター
  • その他

第7章 内分泌検査市場：地域の推定・動向分析

  • 地域の見通し
  • 地域別の内分泌検査市場：マーケットプレースにおける重要なポイント
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Abbott Laboratories
    • AB Sciex
    • Agilent Technologies Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • DiaSorin S.p.A.
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Ortho Clinical Diagnostics
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 3 North America endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America endocrine testing market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 7 U.S. endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 8 U.S. endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Canada endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Europe endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe endocrine testing market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Germany endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 20 UK endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 21 UK endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 23 France endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 24 France endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Italy endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Italy endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Spain endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Spain endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Sweden endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 33 Sweden endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Norway endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 35 Norway endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 36 Norway endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Denmark endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Denmark endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Denmark endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific endocrine testing market, by region, 2018 - 2030 (USD Million)
  • Table 44 China endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 45 China endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 46 China endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Japan endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Japan endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 51 India endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 52 India endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Australia endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Australia endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Australia endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Thailand endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Thailand endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Thailand endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 South Korea endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 60 South Korea endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 61 South Korea endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 63 Latin America endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 64 Latin America endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Latin America endocrine testing market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 67 Brazil endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Brazil endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 70 Mexico endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 71 Mexico endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Argentina endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 74 Argentina endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa endocrine testing market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 80 South Africa endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 81 South Africa endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 86 UAE endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 87 UAE endocrine testing market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait endocrine testing market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait endocrine testing market, by technology, 2018 - 2030 (USD Million)
  • Table 90 Kuwait endocrine testing market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Endocrine testing: Market outlook
  • Fig. 9 Endocrine testing: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Endocrine testing market driver impact
  • Fig. 15 Endocrine testing market restraint impact
  • Fig. 16 Endocrine testing market strategic initiatives analysis
  • Fig. 17 Endocrine testing market: Test type movement analysis
  • Fig. 18 Endocrine testing market: Test type outlook and key takeaways
  • Fig. 19 Estradiol (E2) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Follicle Stimulating Hormone (FSH) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Human Chorionic Gonadotropin (hCG) hormone test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Luteinizing Hormone (LH) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Dehydroepiandrosterone Sulfate (DHEAS) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Progesterone test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Testosterone test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Thyroid Stimulating Hormone (TSH) test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Prolactin test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cortisol test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Insulin test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Endocrine testing market: Technology movement analysis
  • Fig. 32 Endocrine testing market: Technology outlook and key takeaways
  • Fig. 33 Tandem mass spectrometry market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Immunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Monoclonal & polyclonal antibody technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Sensor technology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical chemistry market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Endocrine testing market: End-use movement analysis
  • Fig. 40 Endocrine testing market: End-use outlook and key takeaways
  • Fig. 41 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Commercial laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Ambulatory care centers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Global endocrine testing market: Regional movement analysis
  • Fig. 46 Global endocrine testing market: Regional outlook and key takeaways
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-862-6

Endocrine Testing Market Growth & Trends:

The global endocrine testing market size is expected to reach USD 21.42 billion by 2030, registering a CAGR of 8.4% during the forecast period, according to a new report by Grand View Research, Inc.. The growing prevalence of life style diseases such as obesity coupled with diabetes & thyroid among the adult as well as the geriatric population is driving the need for endocrine testing. The routine endocrine testing in individuals will help in overall maintenance of health and thus this awareness of better health is significantly contributing to the global endocrine testing market growth.

As per the statistics by WHO, more than 39 million children in 2020 who were under the age of 5 were overweight or obese. The sedentary life along with unhealthy diet choices have contributed to obesity as well as diabetes in the general population. This occurrence of diseased conditions has also prompted many researches into the metabolic functions and related hormonal disorders.

Funding from government and private organizations has also driven the scientific community. For instance, the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) by NIH drives many sponsored research programs towards improving health by better understanding of diseases. One such effort by NIDDK was the mid-atlantic symposium conducted in September 2022 for diabetes and obesity research. This will enable scientific knowledge exchange and interactions and allow collaboration at the regional level. Such initiatives will drive the understanding of endocrine function in the human body and will further enable the endocrine testing market growth.

The lack of awareness in underdeveloped and developing countries is anticipated to slow the growth of endocrine testing market. The developing health care settings and absence of reimbursement models restrain the individuals in these regions to undergo routine endocrine testing. However, with the growing consciousness of a healthy system during the COVID-19 pandemic is expected to upswing the testing frequency for these countries as well.

The outbreak of COVID-19 has created lucrative opportunities for the application of endocrine testing. COVID-19 infections cause a systemic disease that injures many organs. Therefore, these patients have many metabolic and hormonal disturbances that led to an increase in the number of endocrine research. For instance, in March 2021, Endocrine society members sanctioned USD 10 billion to support COVID-19 research to identify and understand the short and long-term COVID-19 effects on the endocrine system. Similarly, in September 2020, The American Diabetes Association invested USD 1 million to fund various research projects for investigating the link between diabetes and COVID-19. Thus, it will increase the demand and further boost market growth.

In addition, the limitation of movement and restrictions due to the lockdown encouraged the digital platform for medical consultation and at home sample collection services as well. The availability of point-of-care devices and kits for the detection of hormone levels at home is also driving the overall growth of endocrine testing market.

The market players are also expanding their regional presence due to various factors that are anticipated to grow the endocrine testing market. Collaboration, partnerships and global expansions are some of the business strategies by the key players to drive revenue generation. For instance, in February 2022 Laboratory Corporation of America Holdings (Labcorp) announced opening of a new laboratory in Indiana, U.S. The new diagnostics business in South Bend, Indiana will enhance the company's services and make their offerings accessible to both patients as well as physicians in this region.

Endocrine Testing Market Report Highlights:

  • By test type, the human Chorionic Gonadotropin (hCG) hormone testing accounted for the largest share in 2022, driven by the presence of self-test kits at pharmacy stores, along with tests in laboratories or hospitals for quantitative evaluation. Moreover, the frequency of testing during different weeks of pregnancy and high number of fertile female population are also the contributing factors.
  • By technology, immunoassay dominated the 2022 market, owing to the presence of instruments by key players which uses immunoassay-based detection techniques. The large number of instruments and test panels which rely on immunoassay technology, drives the endocrine testing market growth.
  • By end-user, commercial laboratories contributed majorly to the revenue generation in 2022. The feasibility & availability of variety of testing panels for endocrinology and reproductive functions, services like at home collection and presence of digital platforms led to the increased segment share.
  • North America had the highest revenue generated in 2022 for endocrine testing market. This is attributed to the vast presence of thyroid disorders, diabetes and obesity within the US population. Additionally, developed healthcare and increased spending pattern in this region also led to higher revenue generation.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test Type
    • 1.1.2. Technology
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. Technology outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Endocrine Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Endocrine Testing Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Endocrine Testing: Test Type Estimates & Trend Analysis

  • 4.1. Endocrine Testing Market: Key Takeaways
  • 4.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Estradiol (E2) Test
    • 4.3.1. Estradiol (E2) test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Follicle Stimulating Hormone (FSH) Test
    • 4.4.1. Follicle Stimulating Hormone (FSH) test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 4.5.1. Human Chorionic Gonadotropin (hCG) hormone test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Luteinizing Hormone (LH) Test
    • 4.6.1. Luteinizing Hormone (LH) test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Dehydroepiandrosterone Sulfate (DHEAS) Test
    • 4.7.1. Dehydroepiandrosterone Sulfate (DHEAS) test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Progesterone Test
    • 4.8.1. Progesterone test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Testosterone Test
    • 4.9.1. Testosterone test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Thyroid Stimulating Hormone (TSH) Test
    • 4.10.1. Thyroid Stimulating Hormone (TSH) test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.11. Prolactin Test
    • 4.11.1. Prolactin test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.12. Cortisol Test
    • 4.12.1. Cortisol test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.13. Insulin Test
    • 4.13.1. Insulin test market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.14. Others
    • 4.14.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Endocrine Testing: Technology Estimates & Trend Analysis

  • 5.1. Endocrine Testing Market: Key Takeaways
  • 5.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Tandem Mass Spectrometry
    • 5.3.1. Tandem mass spectrometry market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Immunoassay
    • 5.4.1. Immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Monoclonal & Polyclonal Antibody Technologies
    • 5.5.1. Monoclonal & polyclonal antibody technologies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Sensor Technology
    • 5.6.1. Sensor technology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Clinical Chemistry
    • 5.7.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Endocrine Testing: End-use Estimates & Trend Analysis

  • 6.1. Endocrine Testing Market: Key Takeaways
  • 6.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Commercial Laboratories
    • 6.4.1. Commercial laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Care Centers
    • 6.5.1. Ambulatory care centers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Endocrine Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Endocrine Testing Market by Region: Key Marketplace Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Abbott Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. AB Sciex
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Agilent Technologies Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. bioMerieux SA
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Bio-Rad Laboratories Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. DiaSorin S.p.A.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. F. Hoffmann-La Roche Ltd.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Laboratory Corporation of America Holdings
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Quest Diagnostics Incorporated
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Ortho Clinical Diagnostics
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives